Loading your page…

Pharmaceutical group

Mabxience

11 medicines4 countries

A group of 2 companies with 11 medicines in 4 countries.

Group structure

2 companies in 1 country

Spain2

Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.

Medicines

Every medicine of every company in the group, current ones first.

11 medicines

Medicine	Substance	Country	Status	Authorised
Alymsys	Bevacizumab	EU (EMA)	Authorised	2021
ALYMSYSConcentrato per soluzione per infusione	Bevacizumab	Italy	Authorised
Alymsys 25 mg/ml, concentraat voor oplossing voor infusieConcentraat voor oplossing voor infusie	Bevacizumab	Netherlands	Authorised	2021
ALYMSYS 25 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION25 mg/ml · Concentrado para solución para perfusión	Bevacizumab	Spain	Marketed	2021
DENBRAYCESoluzione iniettabile	Denosumab	Italy	Authorised
Denbrayce	Denosumab	EU (EMA)	Authorised	2025
Denbrayce 120 mg oplossing voor injectieOplossing voor injectie	Denosumab	Netherlands	Authorised	2025
Izamby	Denosumab	EU (EMA)	Authorised	2025
IZAMBYSoluzione iniettabile in siringa pre-riempita	Denosumab	Italy	Authorised
Izamby 60 mg oplossing voor injectie in een voorgevulde spuitOplossing voor injectie	Denosumab	Netherlands	Authorised	2025
IZAMBY 60 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA60 mg · Solución inyectable	Denosumab	Spain	Marketed	2025

Sources and licences

Country	Medicines	Current	Companies
European Union (EMA)	3	3	Companies All medicines
Italy	3	3	Companies All medicines
Netherlands	3	3	Companies All medicines
Spain	2	2	Companies All medicines

Compiled by Prognia from the public medicine and company registers below. Logos are not used.

Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.

European Medicines Agency

Source: European Medicines Agency (EPAR data).

Licence: EMA reuse policy (source acknowledgement required)

Agencia Española de Medicamentos y Productos Sanitarios (CIMA)

Fuente de la información: AEMPS (CIMA).

Licence: AEMPS open data reuse with attribution

Base de données publique des médicaments (ANSM, HAS, UNCAM)

Source: BDPM (ANSM, HAS, UNCAM).

Licence: Licence Ouverte v1.0

Anvisa, Brazil

Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.

Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required

All 12 sources

BDPM / ANSM, HAS and UNCAM

BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained

Licence: BDPM exact Licence Ouverte v1.0 (October 2011)

Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom

Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog

College ter Beoordeling van Geneesmiddelen

Report an error or request removalCorrections from the company itself are welcome.

Mabxience

Group structure

Spain2

Medicines

Know your medicines, with the sources.

Mabxience

Group structure

Spain2

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Other big groups

Group structure

🇪🇸Spain2

Medicines

Know your medicines, with the sources.

Group structure

🇪🇸Spain2

Medicines

Know your medicines, with the sources.

Countries

Therapeutic areas

Top substances

Names in the registers

Sources and licences

At a glance

Spain2

Spain2